Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ragweed allergy vaccine sublingual tablet - ALK-Abello/Merck

Drug Profile

Ragweed allergy vaccine sublingual tablet - ALK-Abello/Merck

Alternative Names: ALK Ragweed Tablet; Ambrosia-artemisiifolia-extract-ALK-Abello; MK-3641; Ragweed AIT; Ragweed allergy immunotherapy - ALK-Abello; Ragweed extract - ALK-Abello; Ragwitek; SCH 039641; SCH 39641; SLITone ULTRA

Latest Information Update: 24 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ALK-Abello
  • Developer ALK-Abello; Merck & Co
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Seasonal allergic rhinitis

Most Recent Events

  • 15 Jan 2019 Efficacy and adverse events data from a phase III trial in Seasonal allergic rhinitis released by ALK-Abello
  • 09 Nov 2018 Merck completes a phase III trial in Seasonal allergic rhinitis in USA, North America, Croatia and Hungary (NCT02478398)
  • 28 Mar 2018 No recent reports of development identified for clinical-Phase-Unknown development in Seasonal-allergic-rhinitis in Hungary (Sublingual, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top